Comparing bladder medication vs surgery for returning low-grade bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether a chemotherapy drug placed directly into the bladder (chemoablation) works as well as surgery followed by chemotherapy for people whose low-grade bladder tumors have come back. It aims to find a less invasive option that still controls the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- Your previous bladder tumor was low-grade and has come back
- The new tumor must be smaller than 2 cm (about 0.8 inches)
- You have not had chemotherapy or BCG treatment in the bladder before (except a single dose after surgery)
- You are not allergic to the drug mitomycin C
- You are not pregnant, breastfeeding, or planning to become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a more targeted way to treat low-grade bladder cancer using chemotherapy placed directly into the bladder. Before treatment, your cancer cells are grown in the lab to see which drug works best for you.
This study tests a new way to give a chemotherapy drug during bladder surgery to help stop the cancer from returning. It is for people with a type of bladder cancer that has not spread into the muscle.
This trial compares two combinations of chemotherapy drugs given directly into the bladder to see which works better for patients whose bladder cancer has not responded to BCG therapy.
This study tests an immunotherapy drug (toripalimab) alone or followed by medication placed directly into the bladder (gemcitabine and mitomycin C) for people with high-risk bladder cancer that has not spread into the muscle wall and that has not responded to or couldn't be handled with BCG therapy. The goal is to see which approach works better.
This trial tests STM-416, given around the time you have surgery to remove recurring bladder tumors, to see if it can reduce the chance the cancer comes back. It is for people with high-risk early bladder cancer (non–muscle-invasive) who have already had standard treatment and now need another TURBT.
This trial tests whether giving mitomycin directly into the bladder before surgery can help people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this approach is safe and effective at preventing cancer from coming back.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.